Alnylam Provides Key 2013 - 2014 Goals for RNAi Therapeutics Pipeline MarketWatch (press release) FAP patients have a life expectancy of five to 15 years from symptom onset, and the only treatment options for early stage disease are liver transplantation and tafamidis (approved in Europe). The mean survival for FAC patients is approximately 2.5 ... |
